- Home
- VATE vs BRNS Comparison
VATE vs BRNS Comparison
Compare VATE & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VATE | BRNS |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 24.1M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VATE | BRNS |
|---|---|---|
| Price | $7.86 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 648.3K | 32.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $0.51 |
| 52 Week High | $21.30 | $1.83 |
Technical Indicators
Market Signals| Indicator | VATE | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 54.41 |
| Support Level | $4.54 | $0.55 |
| Resistance Level | $13.60 | $0.74 |
| Average True Range (ATR) | 1.07 | 0.04 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 20.16 | 65.18 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.